Pomalidomide 4'-PEG3-azide
| Code | Size | Price |
|---|
| TAR-T39806-25mg | 25mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Documents
Further Information
Bioactivity:
Pomalidomide 4'-PEG3-azide is a chemically synthesized conjugate consisting of an E3 ligase ligand-linker conjugate that incorporates the cereblon ligand derived from Pomalidomide, along with a linker. This compound, Pomalidomide 4'-PEG3-azide, is utilized in the synthesis of iRucaparib-TP3 (Compound 3). iRucaparib-TP3, developed through the PROTAC strategy, is an effective degrader of PARP1, derived from Rucaparib.
CAS:
2271036-46-3
Molecular Weight:
474.474
Purity:
0.98
SMILES:
[N-]=[N+]=NCCOCCOCCOCCNc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12
References
Shuai Wang, et al. Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation. Nat Chem Biol. 2019 Dec;15(12):1223-1231.